byiShook Opinion
Mar 3, 2025 - 11:25
AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S. The post AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. appeared first on Investor's Business Daily.
AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.
The post AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. appeared first on Investor's Business Daily.